Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON)- ENROLLMENT ON HOLD 

Posted 3 months ago

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON)- ENROLLMENT ON HOLD 

ClinicalTrials.gov ID NCT06120140

Protocol number Janssen_COCOON

Sponsor  Janssen Research & Development, LLC

ENROLLMENT ON HOLD